This is an early-stage pipeline announcement with no clinical data or regulatory milestones. Monitor for future non-clinical or clinical data readouts and any government stockpiling contracts. The stock may see speculative interest given the outbreak context, but fundamental catalysts remain distant.
Price Chart
Executive Summary
Traws Pharma announced a new broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks, utilizing a proprietary dual-strike mechanism. The company is advancing non-clinical development and scaling manufacturing, with planned interactions with the CDC, NAFDAC, and AMA. No financial data, clinical data, or regulatory milestones were disclosed.
Key Facts
- Announced antiviral program targeting Hantavirus and Ebola Virus Disease outbreaks
- Novel dual-strike mechanism combining host nucleotide depletion and forced lethal incorporation
- Both components of the combination have been safely evaluated in human studies as single agents
- Advancing non-clinical development in BSL-3 and BSL-4 animal models
- Scaling chemical development and manufacturing for potential stockpiling
- Planned interactions with CDC; ongoing with NAFDAC and AMA
- No clinical data, financial figures, or regulatory milestones provided
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Pre-clinical stage — no guarantee of successful clinical translation
- No disclosed funding or budget for the program
- FDA clinical hold on lead program tivoxavir marboxil noted in forward-looking statements
- Regulatory pathways for Hantavirus/Ebola are complex and may require animal rule or emergency use authorization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066623 |
| Document: tm2615712d1_ex99-1.htm | 0001104659-26-066623 |
| Document: 0001104659-26-066623-index-headers.html | 0001104659-26-066623 |
| Document: 0001104659-26-066623-index.html | 0001104659-26-066623 |
| Document: 0001104659-26-066623.txt | 0001104659-26-066623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-1 | $0.3500 | awaiting T+20 | — | $0.3400 (+2.86%) |
Oct 23, 2026 3d ago | 8-K | $0.3510 | awaiting T+20 | — | $0.3400 (+3.13%) |
Oct 20, 2026 6d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3400 (−9.57%) |
Oct 20, 2026 6d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3400 (+9.57%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3400 (+37.04%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3400 (+50.36%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3400 (+55.26%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3400 (−55.26%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3400 (−55.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers